NCT00001962 arm group cc1bbd08f68ee3e8bc61a6e2127bff18 [clinicaltrials_resource:NCT00001962/arm-group/cc1bbd08f68ee3e8bc61a6e2127bff18]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00001962 arm group cc1bbd08f68ee3e8bc61a6e2127bff18 [clinicaltrials_resource:NCT00001962/arm-group/cc1bbd08f68ee3e8bc61a6e2127bff18]
Bio2RDF identifier
NCT00001962/arm-group/cc1bbd08f68ee3e8bc61a6e2127bff18
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 1bbd08f68ee3e8bc61a6e2127bff18
description [clinicaltrials_vocabulary:description]
daclizumab, 1 mg/kg of body we ...... y during the treatment period.
identifier
clinicaltrials_resource:NCT00001962/arm-group/cc1bbd08f68ee3e8bc61a6e2127bff18
title
NCT00001962 arm group cc1bbd08f68ee3e8bc61a6e2127bff18
@en
type
label
NCT00001962 arm group cc1bbd08 ...... bbd08f68ee3e8bc61a6e2127bff18]
@en